drugset / Trial / NCT00437697
Thromboprophylaxis in Critically Ill Patients
RandomizedParallel-groupOpen-labelPrevention
Summary
Intensive care patients are at high risk to develop deep venous thrombosis and pulmonary embolism. Despite anticoagulation with heparin 7% of ICU patients suffer from this serious complication. Optimal regimens for prevention of VTE have been established in medical patients only and are not known for ICU patients. It was therefore the aim of this study to compare the bioavailability of a low molecular weight heparin in ICU patients and in medical patients. Furthermore, we looked wether a 50% dose increase resulted in better bioavailability of this drug.
Timeline
- Start
- 2003-04
- Primary completion
- —
- Completion
- 2005-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalteparin sodium | Other / unclassified | 5000 iu | Subcutaneous |
| Subject | Dalteparin sodium | Other / unclassified | 7500 iu | Subcutaneous |